Pro-proliferative effects were reversed by treatment with GnRHR and 5HTR2A antagonists, suggesting that these neuroendocrine hormones should be included in a list of viable targets for the treatment of osteosarcoma. This evidence concerns the gene GNRHR and osteosarcoma.